Topiramate for Binge Eating Disorder
Topiramate is an effective off-label treatment for binge eating disorder, reducing binge frequency by approximately 90-94% and producing significant weight loss of 4.5-5.9 kg, though it is not FDA-approved for this indication. 1, 2, 3
Evidence Base and Efficacy
The evidence supporting topiramate for binge eating disorder comes primarily from randomized controlled trials showing robust efficacy. The largest multicenter trial (n=394) demonstrated that topiramate reduced binge eating days per week by 3.5 versus 2.5 with placebo (p<0.001), with 58% of patients achieving complete remission compared to 29% on placebo 2. An earlier single-center trial showed even more dramatic results, with 94% reduction in binge frequency and 93% reduction in binge days 3.
Network meta-analysis confirms topiramate and lisdexamfetamine have comparable efficacy for reducing binge episodes (MD -1.63 vs -1.61 respectively), with topiramate producing greater weight loss (-5.5 kg vs -4.6 kg). 4 This positions topiramate as one of the two most effective pharmacologic options for binge eating disorder, despite lacking FDA approval for this indication.
The 2022 AGA guidelines acknowledge that "topiramate has been used to manage some eating disorders, although most published effects are case series or case reports" 1, while the 2023 APA eating disorders guideline does not specifically recommend topiramate for binge eating disorder, instead suggesting lisdexamfetamine or antidepressants 5. However, the research evidence is substantially stronger than these guideline statements suggest.
Dosing Protocol
Start topiramate at 25 mg daily and titrate by 25 mg weekly increments to a target dose of 100-400 mg/day in divided doses. 6 The median effective dose in clinical trials was 212 mg/day (range 50-600 mg/day) 3.
Specific titration schedule:
- Week 1: 25 mg once daily
- Week 2: 50 mg daily (can divide into twice daily dosing)
- Week 3: 75 mg daily in divided doses
- Week 4: 100 mg daily in divided doses
- Continue increasing by 25-50 mg weekly as tolerated up to 200-400 mg/day
The slower titration improves tolerability compared to rapid dose escalation. Most patients respond to doses between 100-300 mg/day 2, 3.
Monitoring Requirements
Monitor serum electrolytes and renal function twice annually due to topiramate's carbonic anhydrase inhibitor properties. 6, 1 Specifically check for:
- Metabolic acidosis (serum bicarbonate)
- Electrolyte abnormalities (particularly potassium)
- Renal function (creatinine clearance)
- Kidney stone risk factors
Obtain monthly pregnancy tests in women of childbearing potential due to increased risk of orofacial clefts with first-trimester exposure 1. Reliable contraception is mandatory.
Monitor for cognitive dysfunction, which is the most common reason for discontinuation (along with paresthesias) 2, 3.
Safety Profile and Contraindications
Discontinuation rates due to adverse events were 16% in the largest trial 2, with the most common side effects being:
- Paresthesias (most frequent)
- Cognitive dysfunction/difficulty concentrating
- Somnolence
- Nausea
- Upper respiratory tract infections
Absolute contraindications:
- Pregnancy or inadequate contraception in women of childbearing potential
- History of kidney stones (topiramate increases stone risk via metabolic acidosis and hypercalciuria) 1
- Untreated narrow-angle glaucoma
Relative contraindications:
- Renal impairment (reduce dose by 50% if CrCl <70 mL/min) 7
- History of cognitive impairment or psychiatric disorders
Clinical Considerations
Topiramate should be considered first-line for patients with binge eating disorder who are overweight or obese and desire weight loss, as it addresses both the binge eating behavior and weight simultaneously 2, 3. This dual benefit distinguishes it from other treatments.
The phentermine-topiramate ER combination (FDA-approved for obesity) showed even greater efficacy in a crossover trial, with 63.6% achieving binge abstinence versus 9.1% on placebo, though this requires additional monitoring for cardiovascular effects from the phentermine component 8.
Taper topiramate gradually when discontinuing (reduce by 25-50 mg every 1-2 weeks) to minimize seizure risk, even in patients without epilepsy 1.
The evidence quality is moderate to high from multiple RCTs 9, 2, 3, though the lack of FDA approval and limited guideline endorsement reflects the fact that most trials were <6 months duration and long-term safety data beyond 1 year are limited.